Dergiler / ENT Updates / 2020 / Cilt: 10 - Sayı: 3

Frequency of adverse reactions after subcutaneous allergen immunotherapy in children

Sayfa
396–401
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The local reactions mostly occurred after SCIT with Apis mellifera venom (100%), followed by house dust mite (20.6%),mold (16.7%) and grass pollen (16.7%).Conclusion: Although SCIT is a safe treatment methodused for allergic diseases, it must be administered only incenters with appropriate emergency equipment due tothe risk of side effects.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Subcutaneous allergen immunotherapy (SCIT)is an effective treatment method for allergic rhinitis,asthma and venom allergy.
📊
Temel Bulgular & Veri:The aim of this study was toevaluate the frequency of adverse reactions in childrenundergoing SCIT.Methods: This retrospective study included patients thatunderwent SCIT in our clinic for a period of five years dueto a diagnosis of Apis mellifera venom allergy or allergic asthma and/or rhinitis. 303 patients were divided intogroups based on the form of SCIT administered and thepresence of injection-related reactions.Results: Mean age at the initiation of SCIT was 10 (range,5-18) years old.
💡
Sonuç & Katkı:The local reactions mostly occurred after SCIT with Apis mellifera venom (100%), followed by house dust mite (20.6%),mold (16.7%) and grass pollen (16.7%).Conclusion: Although SCIT is a safe treatment methodused for allergic diseases, it must be administered only incenters with appropriate emergency equipment due tothe risk of side effects.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Subcutaneous allergen immunotherapy (SCIT)is an effective treatment method for allergic rhinitis,asthma and venom allergy. The aim of this study was toevaluate the frequency of adverse reactions in childrenundergoing SCIT.Methods: This retrospective study included patients thatunderwent SCIT in our clinic for a period of five years dueto a diagnosis of Apis mellifera venom allergy or allergic asthma and/or rhinitis. 303 patients were divided intogroups based on the form of SCIT administered and thepresence of injection-related reactions.Results: Mean age at the initiation of SCIT was 10 (range,5-18) years old. SCIT for aeroallergens was administeredto 289 (95.4%) patients and SCIT for venom to 14 (4.6%)patients. Local reactions were observed in 54 (17.8%) andsystemic reactions developed in 4 (1.3%) patients. The local reactions mostly occurred after SCIT with Apis mellifera venom (100%), followed by house dust mite (20.6%),mold (16.7%) and grass pollen (16.7%).Conclusion: Although SCIT is a safe treatment methodused for allergic diseases, it must be administered only incenters with appropriate emergency equipment due tothe risk of side effects.

🔖

Bu Makaleye Atıf Yap

SASİHUSEYİNOGLU, A. S., DOĞRUEL, D., ALTINTAŞ, D. U. (2020). Frequency of adverse reactions after subcutaneous allergen immunotherapy in children. ENT Updates, Cilt: 10 - Sayı: 3, 396–401. https://ajindex.com/articles/348207

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Tophof MA, Hermanns A, Adelt T, et al. Side effects during subcutaneous immunotherapy in children with allergic diseases. Pediatr Allergy Immunol 2018;29:267-74
  2. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120:25-85
  3. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127:1-55
  4. Bernstein DI, Epstein TEG. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy. Allergy Asthma Proc 2020;41:108-11
  5. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140:950-8
  6. Pedersen SE, Hurd SS, Lemanske RF Jr, et al. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol 2011;46:1-17
  7. Azkur D, Vezir E, Civelek E, et al. The frequency of large local and systemic reactions after subcutaneous immunotherapy in children. [Article in Turkish] Asthma Allergy Immunol 2013;11:37-42
  8. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-74
  9. Soyyiğit Ş, Sin BA. Asthma and Allergen Immunotherapy. [Article in Turkish] Güncel Göğüs Hastalıkları Serisi 2015;3:200-7
  10. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. Ann Allergy Asthma Immunol 2011;107:426-31
  11. Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Hea